Company intelligence / Profile preview

TRIMT GmbH

Ownership: Public · TRIM
Development stage: Phase 1

Overview

Trimt specializes in targeted radiopharmaceuticals for molecular theranostics within the healthcare sector, focusing on cancer diagnosis and therapy. The company primarily focuses its activities on a class of cellular biomarkers called integrins to establish innovative clinical schemes for enhancing lifetimes.

Therapeutic areas: Oncology
Modalities: Targeted radiopharmaceuticals
Industry: Biotech

Drug pipeline

3 assets

68Ga-labeled PD-L1 PET Tracer

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on TRIMT GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRIMT GmbH.

Explore the full profile